Viking Therapeutics, Inc.
24.40USD
-1.4300 (-5.54%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VKTX.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -133 | -164 | -165 | -99 | -75 | -55 | -46 | -37 |
| Net Income | -128 | -158 | -158 | -91 | -66 | -46 | -35 | -25 |
| EPS (Diluted) | -$1.10 | -$1.37 | -$1.39 | -$0.81 | -$0.58 | -$0.41 | -$0.32 | -$0.22 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)